The multi-center clinical study evaluated the device infection and mechanical complication rates for 1,000 patients during the 12 months after they underwent CIED replacement procedures.
According to the study, the Citadel/Centurion cohort at the 90-day follow-up had 95 percent fewer major CIED infections than the pre-defined control cohort. Also, there were only 20 deaths during the period of the study, none related to the use of AIGISRx Antibacterial Envelope.
More Articles on TYRX:
Study: Antibacterial Envelope Reduces SSIs Following Cardiac IED Implantation
Survey: Majority of CEOs Believe Their Influence Can Reduce CIED Infections, Costs
TYRX Announces First Implantation of Antibacterial Stabilization Device
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
